Innovative Enzyme Inhibitor Treatment for Prostate Cancer

By Esha Desai;

Physics & Aerospace Associate; The Lawrenceville School, NJ

1 in 8 men in their lifetime will develop prostate cancer, the second most common cancer in men worldwide. Prostate cancer occurs when prostate gland cells duplicate uncontrollably, causing debilitating symptoms such as bone pain and weakness in the arms and legs. Traditional treatments for prostate cancer are chemotherapy and radiation therapy. However, these treatments are costly, and prostate cancer can easily resist them. Understanding the biology of prostate cancer cells is essential towards creating an innovative and successful treatment.

International researchers, on October 5th, 2025 at Flinders University in Australia and South China University of Technology, have found that two enzymes, PDIA1 and PDIA5, play an important part in the growth of prostate cancer cells. Specifically, these molecules support an androgen receptor protein that fortifies cancer cells against traditional treatment methods. Androgen Receptor proteins signal for testosterone production, which causes cancerous cell proliferation. If these enzymes are blocked, androgen receptor proteins will be destabilized, therefore cutting off tumor development. Furthermore, eliminating PDIA1 and PDIA5 creates a negative feedback loop, since less Androgen receptors proteins signalling for cell growth will decrease testosterone production, leading to the shrinkage of cancer cells. Additionally, this study found that PDIA1 and PDIA5 support cancer cells by relieving stress and sustaining energy output. These enzymes keep the mitochondria running, an organelle that creates energy for the cell, which causes cancer cells to continue functioning when healthy cells die off. By inhibiting these molecules, cancer cells will be inflicted with oxidative stress as the mitochondria is damaged. The scientists concluded that damaging the androgen receptors and blocking cancer cells' energy production are effective ways to treat prostate cancer.

The study found that there was increased effectiveness when combining PDIA1 and PDIA5 inhibitors with the well known prostate cancer treatment, Enzalutamide. This means it took less tablets to observe cancer cell death with the inhibitors than without. Enzalutamide works by decreasing androgen’s ability to bind to androgen receptors. Pairing this medication with PDIA1 and PDIA 5 inhibitors causes more androgen receptor proteins to be blocked since the PDIA molecules are inhibited from acting as a body guard for the proteins. These findings demonstrate how clinical trials involving combination treatments with current drugs and inhibitors could be the future for new medications.

With these findings come limitations on turning enzyme inhibitors into treatment options. Some of the existing compounds in these inhibitors affect healthy cells, so more research needs to be done to make these inhibitors safer in the body. Further investigation into how AR-Therapy and these inhibitors is also necessary, as a combination of these treatments could likely yield effective results for eliminating cancer tumors. In all, these findings display how innovative treatments for prostate cancer are an example of the creation of increasingly innovative medicines by researching the biology of these cancers. 

Works Cited

“Hidden Weakness Makes Prostate Cancer Self-Destruct.” ScienceDaily, 2025, www.sciencedaily.com/releases/2025/11/251110021056.htm.

Mayo Clinic. “Prostate Cancer - Symptoms and Causes.” Mayo Clinic, 2024, www.mayoclinic.org/diseases-conditions/prostate-cancer/symptoms-causes/syc-20353087.

Quinney, Bruno. “Major Study into Prostate Cancer Offers Hope for New Treatments.” Drug Discovery World (DDW), 16 Oct. 2025, www.ddw-online.com/major-study-into-prostate-cancer-offershope-for-new-treatments-37602-202510/. Accessed 4 May 2026.

Xie, Jianling, et al. “Protein Disulfide Isomerases Regulate Androgen Receptor Stability and Promote Prostate Cancer Cell Growth and Survival.” Proceedings of the National Academy of Sciences, vol. 122, no. 42, 14 Oct. 2025, https://doi.org/10.1073/pnas.2509222122. Accessed 15 Oct. 2025.